Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 20/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.40 |
| ▸ | KIT | P10721 | 9/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30086937 | 1.00 | CSF1R (0.40) | CSF1RPDGFRAKITFLT3PDGFRB | |
| SCHEMBL21771990 | 0.87 | CSF1R (0.45) | CSF1RPDGFRAKITFLT3PDGFRB | |
| SCHEMBL30086888 | 0.85 | CSF1R (0.39) | CSF1RPDGFRAKITFLT3PDGFRB | |
| SCHEMBL23888677 | 0.85 | CSF1R (0.39) | CSF1RPDGFRAKITFLT3PDGFRB | |
| SCHEMBL23900709 | 0.83 | PIM1 (0.47) | CSF1RPDGFRAKITFLT3PDGFRB | |
| SCHEMBL30086828 | 0.83 | PIM1 (0.47) | CSF1RPDGFRAKITFLT3PDGFRB | |
| SCHEMBL23888714 | 0.83 | CSF1R (0.43) | CSF1RPDGFRAKITFLT3PDGFRB | |
| SCHEMBL30086979 | 0.83 | CSF1R (0.43) | CSF1RPDGFRAKITFLT3PDGFRB | |
| SCHEMBL23888644 | 0.83 | CSF1R (0.43) | CSF1RPDGFRAKITFLT3PDGFRB | |
| SCHEMBL29100359 | 0.82 | CSF1R (0.43) | CSF1RPDGFRAKITFLT3PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361223-A1 | AMIDE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LTD (CN) | 2025-11-27 | — | — | US | disclosed |
| US-12435062-B2 | Amide compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2025-10-07 | — | — | US | disclosed |
| CN-117777103-A | Amide compound and application thereof | 和记黄埔医药（上海）有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117720520-A | Amide compound and application thereof | 和记黄埔医药（上海）有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-117720519-A | Amide compound and application thereof | 和记黄埔医药（上海）有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-115315422-B | Amide compound and application thereof | 和记黄埔医药（上海）有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20230174513-A1 | AMIDE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-06-08 | — | — | US | disclosed |
| US-20230174513-A1 | AMIDE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-06-08 | — | — | US | disclosed |
| CN-115315422-A | Amide compound and application thereof | 和记黄埔医药（上海）有限公司 | 2022-11-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174513-A1 | AMIDE COMPOUNDS AND USES THEREOF | ASNS, ASS1, NAT1 | CSF1R 2941/4885PDGFRA 3533/4885KIT 2734/4885 |
| US-12435062-B2 | Amide compounds and uses thereof | ASNS, ASS1, NAT1 | CSF1R 2941/4885PDGFRA 3533/4885KIT 2734/4885 |
| US-20250361223-A1 | AMIDE COMPOUNDS AND USES THEREOF | ASNS, NAT1, AADAC | CSF1R 3035/4885PDGFRA 3254/4885KIT 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.